Mario Losen

Effect of oxygen supply on passaging, stabilising and screening of recombinant Hansenula polymorpha production strains in test tube cultures.

Effect of oxygen limitation and medium composition on Escherichia coli fermentation in shake-flask cultures.

DGAT1 overexpression in muscle by in vivo DNA electroporation increases intramyocellular lipid content.

Increased expression of rapsyn in muscles prevents acetylcholine receptor loss in experimental autoimmune myasthenia gravis.

Overexpression of rapsyn in rat muscle increases acetylcholine receptor levels in chronic experimental autoimmune myasthenia gravis.

Improvement of in vivo transfer of plasmid DNA in muscle: comparison of electroporation versus ultrasound.

Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange.

Generation of polyclonal antibodies directed against G protein-coupled receptors using electroporation-aided DNA immunization.

Treatment of myasthenia gravis by preventing acetylcholine receptor modulation.

Immunosuppression of experimental autoimmune myasthenia gravis by mycophenolate mofetil.

Silencing rapsyn in vivo decreases acetylcholine receptors and augments sodium channels and secondary postsynaptic membrane folding.

The expression of the Goodpasture antigen-binding protein (ceramide transporter) in adult rat brain.

The effect of plasma from muscle-specific tyrosine kinase myasthenia patients on regenerating endplates.

Main immunogenic region structure promotes binding of conformation-dependent myasthenia gravis autoantibodies, nicotinic acetylcholine receptor conformation maturation, and agonist sensitivity.

The ceramide transporter and the Goodpasture antigen binding protein: one protein--one function?

The auto-antigen repertoire in myasthenia gravis.

Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction.

Low Current-driven Micro-electroporation Allows Efficient In Vivo Delivery of Nonviral DNA into the Adult Mouse Brain.

In vivo electroporation of the central nervous system: a non-viral approach for targeted gene delivery.

Reduced thymic expression of ErbB receptors without auto-antibodies against synaptic ErbB in myasthenia gravis.

Proteasome inhibition with bortezomib depletes plasma cells and autoantibodies in experimental autoimmune myasthenia gravis.

Paradoxical increase in TAG and DAG content parallel the insulin sensitizing effect of unilateral DGAT1 overexpression in rat skeletal muscle.

Neuropathy-induced spinal GAP-43 expression is not a main player in the onset of mechanical pain hypersensitivity.

Unchanged expression of the ceramide transfer protein in the acute 6-OHDA neurodegenerative model.

The lipid droplet coat protein perilipin 5 also localizes to muscle mitochondria.

Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice.

Goodpasture antigen-binding protein/ceramide transporter binds to human serum amyloid P-component and is present in brain amyloid plaques.

MuSK myasthenia gravis and Lambert-Eaton myasthenic syndrome in the same patient.

Targeting plasma cells with proteasome inhibitors: possible roles in treating myasthenia gravis?

Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4.

Autoantigen induced clonal expansion in immortalized B cells from the peripheral blood of multiple sclerosis patients.

Proteomic analysis of rat tibialis anterior muscles at different stages of experimental autoimmune myasthenia gravis.

Autoantibodies to neurotransmitter receptors and ion channels: from neuromuscular to neuropsychiatric disorders.

Muscle disuse atrophy is not accompanied by changes in skeletal muscle satellite cell content.

MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4.

Complement activation by ceramide transporter proteins.

Clonal heterogeneity of thymic B cells from early-onset myasthenia gravis patients with antibodies against the acetylcholine receptor.

Delivery of DNA into the central nervous system via electroporation.

Proteasome inhibition with bortezomib depletes plasma cells and specific autoantibody production in primary thymic cell cultures from early-onset myasthenia gravis patients.

Glycine receptor antibodies in PERM: a new channelopathy.

Ex vivo and in vivo administration of fluorescent CNA35 specifically marks cardiac fibrosis.

IL-17-producing CD4(+) T cells contribute to the loss of B-cell tolerance in experimental autoimmune myasthenia gravis.

Guidelines for pre-clinical assessment of the acetylcholine receptor-specific passive transfer myasthenia gravis model-Recommendations for methods and experimental designs.

Standardization of the experimental autoimmune myasthenia gravis (EAMG) model by immunization of rats with Torpedo californica acetylcholine receptors - Recommendations for methods and experimental designs.

Detection of Peptide-based nanoparticles in blood plasma by ELISA.